2Tollefsen DM. Does heparin cofactor II modulate atherosclerosis and restenosis[J]?Circulation,2004,109(22):2682-2684.
3Van de WJ, Westendorp RG, Van der Hoeven JG, et al.Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage[J].J Am Soc Nephrol,1996,7(1):145-150.
4Carter AJ, Hicks K, Heldman AW, et al. Clinical evaluation of a microsample coagulation analyzer, and comparison with existing techniques[J].Cathet Cardiovasc Diagn,1996,39(1):97-102.
5Bellomo R, Teede H, Boyce N. Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study[J].Intensive Care Med,1993,19(6):329-332.
6Martin PY, Chevrolet JC, Suter P, et al. Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study[J].Am J Kidney Dis,1994,24(5):806-812.
7Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients[J].Intensive Care Med,2000,26(11):1652-1657.
8Morabito S, Guzzo I, Solazzo A, et al. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding[J].J Nephrol,2003,16(4):566-571.
9Hofbauer R, Moser D, Frass M, et al. Effect of anticoagulation on blood membrane interactions during hemodialysis[J].Kidney Int,1999,56(4):1578-1583.
10Gabutti L, Ferrari N, Mombelli G, et al.The favorable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation[J].J Nephrol,2004,17(6):819-825.
2Reddy B V. Argatroban ues in dialysis patients [J]. Semin Dial, 2004,17(1) :73.
3Swan S K, Hursting M J. The pharmaeokinetics and pharmacody-namics of argatroban: effects of age, gender, and hepatic or renal dysfunction [J]. Pharmacotherapy, 2000,20 (3) :318-329.
4Fareed, Jeske W P. Small-molecule direct antithrombins: argatroban [J]. Best Pract Res Clin HaematoZ, 2004,17(1): 127-138.
5Walenga J M, Ahmad S, Hoppentstedt D, et al. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia [J]. Thromb Res, 2002,105(5) :401-405.
6Swan S K, St Peter J V, Lambrecht L J, et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects [J], Pharmacotherapy, 2000,20(7):756-770.
7Murray P T, Reddy B V, Grossman E J, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease [J]. Kidney Int, 2004, 66 (6) : 2446-2453.
8Tang I Y, Cox D S, Patel K. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia[J]. Ann Pharmacother, 2005,39(2) : 231-236.
9Lewis B E, Grassman E D, Wrona L, et al.Novastan anticoagulation during Renal Stent implant in a patient with heparin indued thrombocy-topenia [J]. Blood Coagul Fibrinolysis, 1997,8 ( 1 ) : 54-58.
10Matsuo T, Yamada T, Yamanashi T, et al. Anticoagulant therapy with MD805 of a hemodialysis patient with heparin- induced thrombocy-topenia [J]. Thromd Res, 1990,58(6):663- 666.
